The stock of Summit Therapeutics PLC (ADR) (NASDAQ:SMMT) is a huge mover today! About 2.66M shares traded hands or 6461.26% up from the average. Summit Therapeutics PLC (ADR) (NASDAQ:SMMT) has risen 31.06% since March 1, 2016 and is uptrending. It has outperformed by 21.82% the S&P500.
The move comes after 6 months positive chart setup for the $106.37 million company. It was reported on Oct, 4 by Barchart.com. We have $48.68 PT which if reached, will make NASDAQ:SMMT worth $196.78 million more.
Summit Therapeutics PLC (ADR) (NASDAQ:SMMT) Ratings Coverage
Out of 3 analysts covering Summit Therapeutic (NASDAQ:SMMT), 2 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 67% are positive. $28 is the highest target while $26 is the lowest. The $27 average target is 58.08% above today’s ($17.08) stock price. Summit Therapeutic has been the topic of 4 analyst reports since August 19, 2015 according to StockzIntelligence Inc. As per Wednesday, August 19, the company rating was maintained by Oppenheimer. H.C. Wainwright initiated the shares of SMMT in a report on Friday, September 16 with “Buy” rating. The company was downgraded on Tuesday, September 1 by Zacks. The stock of Summit Therapeutics PLC (ADR) (NASDAQ:SMMT) has “Buy” rating given on Tuesday, June 21 by Janney Capital.
According to Zacks Investment Research, “Summit Therapeutics PLC is engaged in the discovery and development of drug to treat the fatal muscle wasting disease Duchenne Muscular Dystrophy and infections caused by the bacteria C. difficile. Summit Therapeutics PLC is headquartered in Abingdon, the United Kingdom.”
More notable recent Summit Therapeutics PLC (ADR) (NASDAQ:SMMT) news were published by: Schaeffersresearch.com which released: “Buzz Stocks: Apple Inc., Aralez Pharmaceuticals Inc, and Summit Therapeutics …” on October 04, 2016, also Marketwatch.com with their article: “Summit Therapeutics PLC ADR” published on April 22, 2011, Schaeffersresearch.com published: “Biotech Buzz: Axovant Sciences Ltd, Summit Therapeutics PLC (ADR), and Mylan NV” on September 26, 2016. More interesting news about Summit Therapeutics PLC (ADR) (NASDAQ:SMMT) were released by: Quotes.Wsj.com and their article: “DOW JONES, A NEWS CORP COMPANY” published on February 13, 2011 as well as Businessfinancenews.com‘s news article titled: “Summit Therapeutics Receives Phase 2 Trial Approval for DMD Patients” with publication date: January 21, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.